# EDGAR Filing Document

**Accession Number:** 0001560293
**File Stem:** 0001213900-26-073332
**Filing Date:** 2026-6
**Character Count:** 23575
**Document Hash:** de8746bab426c6cbd868aff6af5cb39c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-073332.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001213900-26-073332

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**EFFECTIVENESS DATE**: 20260629

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tenon Medical, Inc.
- **CENTRAL INDEX KEY:** 0001560293
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455574718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-297142
- **FILM NUMBER:** 261137831

**BUSINESS ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032
- **BUSINESS PHONE:** (408) 649-5760

**MAIL ADDRESS:**
- **STREET 1:** 104 COOPER CT.
- **CITY:** LOS GATOS
- **STATE:** CA
- **ZIP:** 95032

**As filed with the U.S. Securities and Exchange Commission on June 29, 2026.**

Registration No. 333-296952

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Tenon Medical, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **3841** | **45-5574718** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification Number) |

---

**104 Cooper Court**

**Los Gatos, CA 95032**

**(408) 649-5760**

(Address, including zip code, and telephone number, including area code,

of registrant's principal executive offices)

**Steven M. Foster**

**Chief Executive Officer and President**

**Tenon Medical, Inc.**

**104 Cooper Court**

**Los Gatos, CA 95032**

**(408) 649-5760**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

<u>Copies to</u>:

---

| | |
|:---|:---|
| **Ross D. Carmel, Esq.** | **Richard A. Friedman, Esq.** |
| **Jeffrey P. Wofford, Esq.** | **Sean F. Reid, Esq.** |
| **Anna Chaykina, Esq.** | **Sheppard, Mullin, Richter & Hampton LLP** |
| **Sichenzia Ross Ference Carmel LLP** | **30 Rockefeller Plaza** |
| **1185 Avenue of Americas, 26<sup>th</sup> Floor** | **New York, New York 10112** |
| **New York, New York 10036** | **Telephone: (212) 653-8700** |
| **Telephone: (212) 930-9700** |  |

---

Approximate date of commencement of proposed sale to the public: **As soon as practicable after the effective date of this Registration Statement.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.**

**EXPLANATORY NOTE**

This registration statement is being filed pursuant to Rule 462(b) and General Instruction V to Form S-1, both promulgated under the Securities Act of 1933, as amended, and is being filed for the sole purpose of increasing the proposed maximum aggregate offering price of the securities offered by Tenon Medical, Inc. (the "Company") by $443,800. This registration statement relates to the Company's registration statement on Form S-1 (File No. 333-296952), originally filed by the Company with the Securities and Exchange Commission on June 22, 2026 (the "Prior Registration Statement"), and declared effective by the Securities and Exchange Commission on June 29, 2026. The contents of the Prior Registration Statement are incorporated herein by reference.

The required opinion, consents and filing fee-related information are listed on an Exhibit Index attached hereto and filed herewith. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

**Item 16. Exhibits and Financial Statement Schedules.**

All exhibits filed with or incorporated by reference in Registration Statement No. 333-296952 are incorporated by reference into, and shall be deemed to be part of, this Registration Statement, except for the following, which are filed herewith:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 5.1 | [Opinion of Legal Counsel to the Registrant](ea029640601ex5-1.htm) |
| 23.1 | [Consent of Haskell & White LLP](ea029640601ex23-1.htm) |
| 23.2 | [Consent of Counsel to Registrant (included in Exhibit 5.1).](ea029640601ex5-1.htm) |
| 107 | [Filing Fee Table.](ea029640601ex-fee.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Gatos, State of California, on June 29, 2026.

---

| | |
|:---|:---|
| **Tenon Medical, Inc.** | **Tenon Medical, Inc.** |
| By: | */s/ Steven M. Foster* |
|  | Steven M. Foster<br> Chief Executive Officer and President (Principal Executive Officer) |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Position** | **Date** |
| /s/ Steven M. Foster | Chief Executive Officer and President, Director | June 29, 2026 |
| Steven M. Foster | (Principal Executive Officer) |  |
| \* | Chief Technology Officer and Director | June 29, 2026 |
| Richard Ginn |  |  |
| /s/ Kevin Williamson | Chief Financial Officer (Principal Financial Officer) | June 29, 2026 |
| Kevin Williamson |  |  |
| \* | Director | June 29, 2026 |
| Richard Ferrari |  |  |
| \* | Director | June 29, 2026 |
| Ivan Howard |  |  |
| \* | Director | June 29, 2026 |
| Kristine Jacques |  |  |
| \* | Director | June 29, 2026 |
| Robert K. Weigle |  |  |
| \* | Director | June 29, 2026 |
| Stephen H. Hochschuler, M.D. |  |  |

---

---

| |
|:---|
| \*By: |
| /s/ Steven M. Foster |
| Steven M. Foster<br> Attorney-in-Fact |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ea029640601_ex5-1img1.jpg)

June 29, 2026

Tenon Medical, Inc.

104 Cooper Ct.

Los Gatos, CA 95032

Ladies and Gentlemen:

We have acted as counsel to Tenon Medical, Inc., a Delaware corporation (the "Company"), in connection with the preparation of the Company's registration statement on Form S-1 (File No. 333-296952) (such registration statement, as amended through the date hereof, the "Initial Registration Statement"), and the preliminary prospectus forming a part of the Initial Registration Statement (the "Prospectus"), under the Securities Act of 1933, as amended (the "Securities Act"), initially filed by the Company with the Securities and Exchange Commission (the "Commission") on June 22, 2026, as thereafter amended or supplemented, and declared effective by the Commission on June 29, 2026 , and a second registration statement on Form S-1 filed with the Commission on June 29, 2026 pursuant to Rule 462(b) promulgated under the Securities Act (the "462(b) Registration Statement", and together with Initial Registration Statement and Prospectus the "Registration Statement"). The Registration Statement relates to the registration of (i) up to $4,200,000 shares (the "Shares") of common stock of the Company, par value $0.001 per share (the "Common Stock") or up to $4,200,000 pre-funded warrants (the "Pre-Funded Warrants") together with (ii) common stock purchase warrants to purchase up to $6,300,000 shares of Common Stock (the "Common Warrants"), (iii) the warrants to purchase up to $151,200 shares of Common Stock to be issued to the placement agent in the offering (the "Placement Agent Warrants" and together with the Common Warrants and the Pre-Funded Warrants, the "Warrants"); and (iv) the shares of Common Stock underlying the Warrants (the "Warrant Shares"). For each Pre-Funded Warrant the Company sells, the number of Shares offered will be decreased on a one-for-one basis.

In connection with this opinion, we have examined originals or copies (certified or otherwise identified to our satisfaction) of (i) the Company's Second Amended and Restated Certificate of Incorporation, as amended, as currently in effect, (ii) the Company's Bylaws, as amended, as currently in effect, (iii) the Registration Statement and related Prospectus, (iv) the form of the Securities Purchase Agreement; (v) the form of Pre-Funded Warrant, (vi) the forms of the Warrants, (vii) the form of Warrant Agency Agreement, (viii) the form of the Placement Agency Agreement, and (ix) such corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials or of officers and representatives of the Company, as we have deemed relevant and necessary as a basis for the opinion hereinafter set forth.

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies, and the authenticity of the originals of such latter documents. As to certain questions of fact material to this opinion, we have relied upon certificates or comparable documents of officers and representatives of the Company and have not sought to independently verify such facts.

Based on the foregoing, and subject to the assumptions, qualifications, limitations and exceptions set forth herein, we are of the opinion that:

1. The Shares, when issued against payment therefor, will be validly issued, fully paid and non-assessable shares of Common Stock;

2. The Pre-Funded Warrants, when issued against payment therefor, will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with their terms, except that (i) such enforceability may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors' rights in general and (ii) the remedies of specific performance and injunctive and other forms of injunctive relief may be subject to equitable defenses;

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

![](ea029640601_ex5-1img1.jpg)

3. The Warrant Shares have been duly authorized by all necessary corporate action on the part of the Company and, when issued, sold and delivered by the Company pursuant to the exercise of the applicable Warrants against payment therefor, if any is payable, will be validly issued, fully paid and non-assessable shares of Common Stock; and

4. The Warrants, when issued against payment therefor pursuant to the terms of the Securities Purchase Agreement related to the Prospectus, will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with their terms, except that (i) such enforceability may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors' rights in general and (ii) the remedies of specific performance and injunctive and other forms of injunctive relief may be subject to equitable defenses.

The opinion expressed herein is limited to the General Corporation Law of the State of Delaware (including reported judicial decisions interpreting the General Corporation Law of the State of Delaware) and, with respect to the enforceability of the Pre-Funded Warrants and the Warrants, the laws of the State of New York, and we express no opinion as to the effect on the matters covered by this letter of the laws of any other jurisdiction.

We assume no obligation to update or supplement any of our opinions to reflect any changes of law or fact that may occur. We hereby consent to the filing of this letter as an exhibit to the Registration Statement and to the reference to our firm under the caption "Legal Matters" in the Prospectus which is a part of the Registration Statement. In giving such consents, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| */s/ Sichenzia Ross Ference Carmel LLP* |
| Sichenzia Ross Ference Carmel LLP |

---

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036

T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW

## Exhibit 23.1

**Exhibit 23.1**

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement on Form S-1 (Registration No. 333-296952) of Tenon Medical, Inc. (the "Company") of our report dated March 27, 2026, relating to our audits of the Company's financial statements as of December 31, 2025 and 2024, and for each of the years then ended, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.

We also consent to the reference to us under the heading "Experts" in this Registration Statement.

---

| |
|:---|
| */s/ Haskell & White LLP* |
| HASKELL & WHITE LLP |

---

Irvine, California

June 29, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-1**

**Tenon Medical, Inc.**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Equity | Common stock, par value $0.001 per share | (1) | 457(o) |  | $| $175000.00 | 0.0001381 | $24.17 |
| Fees to be Paid | Equity | Pre-funded warrants to purchase common stock, $0.001 par value per share | (2) | Other |  |  |  | 0.0001381 | 0.00 |
| Fees to be Paid | Equity | Common stock, $0.001 par value per share, underlying the pre-funded warrants | (3) | 457(o) |  |  | 0.00 | 0.0001381 | 0.00 |
| Fees to be Paid | Equity | Common stock purchase warrants to purchase common stock | (4) | Other |  |  |  | 0.0001381 | 0.00 |
| Fees to be Paid | Equity | Common stock, par value $0.001 per share, underlying Common stock purchase warrants | (5) | 457(o) |  |  | 262500.00 | 0.0001381 | 36.25 |
| Fees to be Paid | Equity | Underwriter Warrants to purchase common stock | (6) | Other |  |  |  | 0.0001381 | 0.00 |
| Fees to be Paid | Equity | Common stock, par value $0.0001 per share, underlying underwriter warrants | (7) | 457(o) |  | $| $6300.00 | 0.0001381 | $0.87 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $443800.00 |  | 61.29 |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  | 0.00 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $61.29 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. No separate fee is required pursuant to Rule 457(g) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. No separate fee is required pursuant to Rule 457(g) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. In addition to the common stock set forth in this table, pursuant to Rule 416 under the Securities Act, this registration statement also registers such indeterminate number of common stock as may become issuable upon exercise of the pre-funded warrants and common stock purchase warrants.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. No separate fee is required pursuant to Rule 457(g) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Represents warrants to purchase an amount of shares of our common stock equal to 3% of the number of shares of common stock and/or pre-funded warrants and/or common stock purchase warrants issued in this offering (including any shares sold to cover over-allotments, if any), at an exercise price per share equal to 120% of the public offering price).